MELOXICAM Drug Interactions
Also known as: meloxicam
MELOXICAM (brand name: meloxicam) is a NSAIDs. 1 INDICATIONS AND USAGE Meloxicam Tablets are non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥ 60 kg ( 1.3 ) 1.1 Osteoarthritis (OA) Meloxicam tablets are indicated for…MELOXICAM has 17 documented drug interactions in our database, including 0 contraindicated, 16 major, 1 moderate, and 0 minor interactions.
0
Contraindicated
16
Major
1
Moderate
0
Minor
Combining meloxicam with aspirin 81 mg significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided unless specifically recommended and closely monitored by your doctor.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Aspirin 81 mg is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, preventing thromboxane A2 formation and thus platelet aggregation. The combined antiplatelet effects and gastrointestinal mucosal damage from both drugs lead to an additive increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage, perforation), but also other sites like bruising or epistaxis. The risk of serious GI bleeding can be several times higher compared to either drug alone. Symptoms may include black, tarry stools, vomiting blood, or severe abdominal pain. This combination should generally be avoided. If both agents are deemed absolutely necessary, the patient must be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be co-prescribed to reduce gastrointestinal risk. Consider alternative pain management strategies that do not involve NSAIDs, or use the lowest effective dose of meloxicam for the shortest duration possible.
Combining meloxicam with apixaban significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to the serious bleeding potential.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Apixaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing clot formation. The concurrent use leads to additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage from the NSAID.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis). Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2-3 fold compared to DOACs alone, with a significant portion being GI bleeds. Other potential bleeding sites include intracranial hemorrhage or genitourinary bleeding. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies first. If no other option exists, use the lowest effective dose of meloxicam for the shortest possible duration, and monitor closely for any signs of bleeding. Proton pump inhibitor (PPI) co-prescription may reduce GI bleeding risk but does not eliminate it. Regular blood count monitoring is advisable. Consider alternative analgesics like acetaminophen.
Combining meloxicam with rivaroxaban significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided.
Mechanism
Meloxicam, an NSAID, inhibits cyclooxygenase enzymes, which reduces prostaglandin synthesis. This leads to impaired platelet aggregation and can cause direct gastric mucosal irritation. Rivaroxaban is a direct factor Xa inhibitor, which prevents clot formation. The combination results in additive antiplatelet and anticoagulant effects, significantly increasing bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding. This can manifest as gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis), intracranial hemorrhage, hematuria, or excessive bleeding from minor injuries. The risk of serious gastrointestinal bleeding can be several-fold higher compared to either drug alone. This combination should generally be avoided due to the high bleeding risk. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (like celecoxib) with extreme caution, proton pump inhibitor co-therapy, and close monitoring for bleeding. Patients should be educated on bleeding signs and symptoms and seek immediate medical attention if they occur. If possible, consider alternative analgesics like acetaminophen.
Combining meloxicam with argatroban significantly increases your risk of serious bleeding, including stomach bleeding. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet function. Argatroban is a direct thrombin inhibitor that prevents fibrin formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, severely impairing hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also hemorrhage at other sites. This can manifest as blood in stool, vomiting blood, easy bruising, or prolonged bleeding from minor cuts. The risk of major bleeding can be several-fold higher compared to either drug alone. This combination should be avoided if possible. If concomitant use is absolutely necessary, patients must be closely monitored for signs and symptoms of bleeding, and argatroban dosage may need adjustment with frequent coagulation monitoring (aPTT). Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If an NSAID is unavoidable, a COX-2 selective agent might be considered, but still carries significant risk.
Combining meloxicam (an NSAID) with bivalirudin (an anticoagulant) significantly increases your risk of serious bleeding. This combination should generally be avoided.
Mechanism
Meloxicam inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa, increasing the risk of bleeding. Bivalirudin directly inhibits thrombin, preventing clot formation. The concurrent use of these agents leads to additive antihemostatic effects, synergistically increasing the likelihood of hemorrhage.
Clinical Management
This interaction significantly elevates the risk of major bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other site-specific bleeding. The risk of GI bleeding can be 3-15 times higher compared to anticoagulant monotherapy, potentially leading to severe complications requiring hospitalization or blood transfusions. Concurrent use of meloxicam and bivalirudin should be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or agents with a lower bleeding risk profile, such as acetaminophen. Closely monitor for any signs of bleeding (e.g., black/tarry stools, unusual bruising, epistaxis) if co-administration cannot be avoided, and use the lowest effective dose for the shortest duration.
Combining meloxicam with warfarin significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor may need to adjust your medications or monitor you very closely.
Mechanism
Meloxicam, an NSAID, inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa. Warfarin, an anticoagulant, inhibits vitamin K-dependent clotting factors. The combination leads to additive antiplatelet effects and increased anticoagulant activity, significantly elevating bleeding risk.
Clinical Management
This interaction can lead to severe bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other internal bleeding. The risk of major GI bleeding is estimated to be 3 to 15 times higher when NSAIDs are co-administered with warfarin compared to warfarin alone. Avoid concurrent use of meloxicam and warfarin if possible. If co-administration is unavoidable, closely monitor INR and signs of bleeding (e.g., black/tarry stools, unusual bruising). Consider alternative pain management strategies or a gastroprotective agent (e.g., PPI) if NSAID use is essential. Discuss with your physician for alternative pain relief.
Combining meloxicam with dabigatran significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Dabigatran is a direct thrombin inhibitor, preventing clot formation. The concurrent use of these agents leads to additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage from the NSAID.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding, which can be life-threatening. Studies show that combining NSAIDs with DOACs like dabigatran can increase the risk of major bleeding by 2 to 3 times compared to dabigatran alone. Other bleeding sites include intracranial hemorrhage, genitourinary, and epistaxis. Avoid concurrent use of meloxicam and dabigatran if possible. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course with close monitoring for bleeding signs and symptoms. Proton pump inhibitors (PPIs) may be considered for gastrointestinal protection if the combination cannot be avoided, but this does not eliminate the increased bleeding risk. Regular monitoring for signs of bleeding (e.g., black tarry stools, unusual bruising, blood in urine) is crucial.
Combining meloxicam with edoxaban significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing clot formation. The combined effect leads to an additive increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding, which can manifest as dark stools, vomiting blood, or severe abdominal pain. Studies show a significantly elevated risk of major bleeding events, potentially 2-3 times higher than with either drug alone. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies first. If no alternatives exist, use the lowest effective dose for the shortest possible duration, and monitor closely for signs of bleeding. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk, but this does not eliminate the overall increased bleeding risk. Reassess the need for both medications.
Combining meloxicam with heparin significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Heparin is an anticoagulant that directly inhibits various coagulation factors. The combined effect leads to an additive impairment of hemostasis and increased risk of bleeding.
Clinical Management
Patients are at a substantially increased risk of serious bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. The risk of gastrointestinal bleeding can be 3 to 15 times higher when NSAIDs are combined with anticoagulants compared to anticoagulants alone. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from minor cuts. This combination should be avoided whenever possible. If concurrent use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and consideration of gastroprotective agents (e.g., PPIs). Alternative pain management strategies that do not increase bleeding risk should be explored. If bleeding occurs, prompt medical attention is required.
Combining meloxicam (an NSAID) with enoxaparin (a blood thinner) significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Meloxicam inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa, increasing the risk of bleeding. Enoxaparin directly inhibits Factor Xa, preventing clot formation. The concurrent use of these agents leads to additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also intracranial hemorrhage or other site-specific bleeding. Studies show that NSAID use with anticoagulants can increase GI bleeding risk by 3 to 15 times. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from cuts. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and for the shortest duration possible. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is unavoidable, a COX-2 selective agent might be considered, but still carries significant risk.
Combining meloxicam with fondaparinux significantly increases your risk of serious bleeding, including stomach bleeding. It is generally recommended to avoid this combination.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Fondaparinux is a selective factor Xa inhibitor, which prevents clot formation. The combination results in additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage from the NSAID.
Clinical Management
This interaction primarily leads to a significantly increased risk of bleeding, particularly gastrointestinal bleeding, but also bleeding at other sites. The risk of serious gastrointestinal bleeding can be several-fold higher (e.g., 3-15 times) when NSAIDs are combined with anticoagulants compared to either agent alone. Patients may experience symptoms such as black, tarry stools, blood in vomit, easy bruising, or prolonged bleeding from minor cuts. This combination should generally be avoided due to the high risk of serious bleeding. If both agents are absolutely necessary, extremely close monitoring for signs of bleeding is crucial, and a proton pump inhibitor (PPI) should be co-administered for gastroprotection. Consider alternative pain management strategies that do not involve NSAIDs, or alternative anticoagulants if clinically appropriate and feasible.
Combining meloxicam with dipyridamole significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole is an antiplatelet agent that inhibits phosphodiesterase, leading to increased cyclic AMP and reduced platelet aggregation. The concurrent use of these agents results in an additive antiplatelet effect, significantly increasing the risk of hemorrhage.
Clinical Management
Patients are at a substantially increased risk of serious bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other forms of systemic bleeding. The risk of major GI bleeding with NSAIDs combined with antiplatelets can be several-fold higher than with either agent alone, potentially leading to anemia, hospitalization, or life-threatening complications. This combination should generally be avoided due to the high risk of bleeding. If concurrent use is unavoidable, patients must be closely monitored for signs and symptoms of bleeding (e.g., black/tarry stools, unusual bruising, prolonged bleeding from cuts). Consider alternative pain management strategies or alternative antiplatelet agents with a lower bleeding risk, if appropriate and clinically feasible. Proton pump inhibitor prophylaxis may be considered if NSAID use is absolutely necessary.
Combining meloxicam with ticagrelor significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor may need to adjust your medications or monitor you closely.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Ticagrelor is a potent antiplatelet agent that directly inhibits platelet aggregation. The combined antiplatelet effects and gastrointestinal mucosal damage synergistically increase bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or life-threatening. This combination can increase the risk of major bleeding events by several-fold compared to either drug alone, potentially leading to anemia, hematemesis, melena, or hemorrhagic stroke. This combination should generally be avoided due to the high bleeding risk. If concurrent use is absolutely necessary, the lowest effective dose of meloxicam for the shortest duration should be used, along with a proton pump inhibitor (PPI) for gastroprotection. Close monitoring for signs of bleeding is essential, and alternative pain management strategies should be explored.
Combining meloxicam with clopidogrel significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair platelet function and disrupt the protective gastric mucosal barrier. Clopidogrel is an antiplatelet agent that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing their aggregation. The concurrent use leads to additive antiplatelet effects and increased gastrointestinal damage, significantly elevating bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), which can be severe or even fatal. Symptoms may include black, tarry stools; vomiting blood; or unusual bruising. The risk of major GI bleeding with NSAID plus antiplatelet therapy is significantly elevated compared to either drug alone. This combination should be avoided if possible. If concomitant use is unavoidable, patients should be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be co-prescribed to reduce GI bleeding risk. Consider alternative pain management strategies or alternative antiplatelet agents if appropriate, and discuss with a healthcare provider.
Combining meloxicam with prasugrel significantly increases your risk of serious bleeding, including stomach bleeding. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair the protective mucosal barrier in the gastrointestinal tract and inhibit platelet aggregation. Prasugrel is a potent antiplatelet agent that irreversibly blocks the P2Y12 receptor on platelets, preventing platelet activation and aggregation. The concurrent use of these agents results in additive antiplatelet effects and increased gastrointestinal damage, leading to a substantially elevated risk of bleeding.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also bleeding from other sites. This risk can be several-fold higher compared to monotherapy. Symptoms may include black, tarry stools, vomiting blood, or unusual bruising. Avoid concurrent use of meloxicam and prasugrel due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID with concomitant proton pump inhibitor (PPI) therapy, though the bleeding risk remains significant. Closely monitor for signs and symptoms of bleeding if co-administration cannot be avoided.
Combining meloxicam with cilostazol significantly increases your risk of serious bleeding, including stomach or intestinal bleeding. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa. Cilostazol is a phosphodiesterase-3 inhibitor that directly inhibits platelet aggregation and causes vasodilation. The co-administration of these agents results in additive antiplatelet effects and increased gastrointestinal mucosal damage, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage). Other potential bleeding sites include intracranial, genitourinary, and skin/soft tissue. Patients may experience symptoms like black, tarry stools, vomiting blood, or unusual bruising. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is absolutely necessary, use the lowest effective doses for the shortest duration possible, and monitor closely for signs of bleeding. Consider alternative pain management strategies or alternative antiplatelet agents if appropriate. Proton pump inhibitor prophylaxis may be considered to reduce GI bleeding risk if no alternatives exist.
Concomitant use of meloxicam and ibuprofen, both nonsteroidal anti-inflammatory drugs (NSAIDs), significantly increases the risk of serious gastrointestinal adverse events, including ulcers, bleeding, and perforation. It also elevates the risk of acute kidney injury and cardiovascular thrombotic events without providing additional analgesic benefit.
Mechanism
Both meloxicam and ibuprofen inhibit prostaglandin synthesis through cyclooxygenase (COX) enzymes. Their combined use leads to an additive pharmacodynamic effect, resulting in greater suppression of protective prostaglandins in the gastrointestinal tract and kidneys.
Clinical Management
Avoid concomitant use of meloxicam and ibuprofen. If an NSAID is required, use a single agent at the lowest effective dose for the shortest duration possible. Consider alternative analgesic strategies or gastroprotective agents if NSAID therapy is unavoidable and the patient is at high risk.
For complete prescribing information:
View full MELOXICAM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.